<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00489489</url>
  </required_header>
  <id_info>
    <org_study_id>PDY6045</org_study_id>
    <secondary_id>2006-003134-14</secondary_id>
    <secondary_id>HMR1726D-2003</secondary_id>
    <nct_id>NCT00489489</nct_id>
  </id_info>
  <brief_title>Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis</brief_title>
  <official_title>A Randomized, Multinational, Double-Blind, Placebo-Controlled, Parallel-Group Design Pilot Study to Estimate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamic Effects of Teriflunomide for 24 Weeks When Added to Treatment With Interferon-beta in Subjects With Multiple Sclerosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective was to estimate the tolerability and safety of 2 doses of teriflunomide
      administered once daily for 24 weeks, compared with placebo, in patients with multiple
      sclerosis [MS] with relapses who were on a stable dose of interferon-β [IFN-β].

      Secondary objectives were:

        -  to estimate the effects of the 2 doses of teriflunomide, compared to placebo, in
           combination with a stable dose of IFN-β on Magnetic Resonance Imaging [MRI] parameters,
           relapse rate and patient-reported fatigue;

        -  to perform pharmacokinetic analyses of the 2 doses of teriflunomide in combination with
           a stable dose of IFN-β.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study period per participant was approximatively 44 weeks broken down as follows:

        -  Screening period up to 4 weeks,

        -  24-week double-blind treatment period*,

        -  16-week post-treatment elimination follow-up period.

      '*' participants successfully completing the week 24 visit were offered the opportunity to
      enter the optional long-term extension study LTS6047 - NCT00811395.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overview of Adverse Events [AE]</measure>
    <time_frame>from first study drug intake up to 112 days after last intake or up to the first intake in the extension study LTS6047, whichever occured first (40 weeks max)</time_frame>
    <description>AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overview of AE With Potential Risk of Occurrence</measure>
    <time_frame>from first study drug intake up to 112 days after last intake or up to the first intake in the extension study LTS6047, whichever occured first (40 weeks max)</time_frame>
    <description>AE with potential risk of occurrence were defined as follows:
Hepatic disorders;
Immune effects, mainly effects on bone marrow and infection;
Pancreatic disorders;
Malignancy;
Skin disorders, mainly Hair loss and Hair thinning;
Pulmonary disorders;
Hypertension;
Peripheral neuropathy;
Psychiatric disorders;
Hypersensitivity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver Function: Number of Participants With Potentially Clinically Significant Abnormalities (PCSA)</measure>
    <time_frame>from first study drug intake up to 112 days after last intake or up to the first intake in the extension study LTS6047, whichever occured first (40 weeks max)</time_frame>
    <description>PCSA values are abnormal values considered medically important by the Sponsor according to predefined criteria based on literature review.
Hepatic parameters thresholds were defined as follows:
Alanine Aminotransferase [ALT] &gt;3, 5, 10 or 20 Upper Normal Limit [ULN];
Aspartate aminotransferase [AST] &gt;3, 5, 10 or 20 ULN;
Alkaline Phosphatase &gt;1.5 ULN;
Total Bilirubin [TB] &gt;1.5 or 2 ULN;
ALT &gt;3 ULN and TB &gt;2 ULN;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebral Magnetic Resonance Imaging [MRI] Assessment: Change From Baseline in Total Lesion Volume (Burden of Disease)</measure>
    <time_frame>baseline (before randomization) and 24 weeks</time_frame>
    <description>Total lesion volume is the sum of the total volume of all T2-lesions and the total volume of all T1-hypointense post-gadolinium lesions measured through T2/proton density scan analysis and gadolinium-enhanced T1 scan analysis.
Least-square means were estimated using a Mixed-effect model with repeated measures [MMRM] on cubic root transformed volume data (treatment group, region of enrollment, IFN-β dose level, visit, treatment-by-visit interaction, baseline value (cubic root transformed), and baseline-by-visit interaction as factors).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral MRI Assessment: Number of Gd-enhancing T1-lesions Per Scan (Poisson Regression Estimates)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of Gd-enhancing T1-lesions per scan is obtained from the total number of Gd-enhancing T1-lesions observed during the study divided by the total number of scans performed during the study.
To account for the different number of scans among participants, a Poisson regression model with robust error variance was used (total number of Gd-enhancing T1-lesions as response variable; log-transformed number of scans as &quot;offset&quot; variable; treatment group, region of enrollment, IFN-β dose level and baseline number of Gd-enhancing T1-lesions as covariates).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral MRI Assessment: Volume of Gd-enhancing T1-lesions Per Scan</measure>
    <time_frame>24 weeks</time_frame>
    <description>Total volume of Gd-enhancing T1-lesions per scan is obtained from the sum of the volumes of Gd-enhancing T1-lesions observed during the study divided by the total number of scans performed during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Relapse Rate [ARR]: Poisson Regression Estimates</measure>
    <time_frame>24 weeks</time_frame>
    <description>ARR is obtained from the total number of confirmed relapses that occured during the treatment period divided by the sum of the treatment durations.
Each episode of relapse - appearance, or worsening of a clinical symptom that was stable for at least 30 days, that persisted for a minimum of 24 hours in the absence of fever - was to be confirmed by an increase in Expanded Disability Status Scale [EDSS] score or Functional System scores.
To account for the different treatment durations among participants, a Poisson regression model with robust error variance was used (total number of confirmed relapses as response variable; log-transformed treatment duration as &quot;offset&quot; variable; treatment group, region of enrollment and IFN-β dose level as covariates).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic [PK]: Teriflunomide Plasma Concentration</measure>
    <time_frame>24 weeks</time_frame>
    <description>Plasma concentrations of teriflunomide were measured using validated liquid chromatography-tandem mass spectrometry methods.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Teriflunomide 7 mg + IFN-β</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teriflunomide 7 mg once daily concomitantly with Interferon-β (IFN-β) for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teriflunomide 14 mg + IFN-β</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teriflunomide 14 mg once daily concomitantly with Interferon-β (IFN-β) for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + IFN-β</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (for Teriflunomide) once daily concomitantly with Interferon-β (IFN-β) for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriflunomide</intervention_name>
    <description>Film-coated tablet
Oral administration</description>
    <arm_group_label>Teriflunomide 7 mg + IFN-β</arm_group_label>
    <arm_group_label>Teriflunomide 14 mg + IFN-β</arm_group_label>
    <other_name>HMR1726</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Teriflunomide)</intervention_name>
    <description>Film-coated tablet
Oral administration</description>
    <arm_group_label>Placebo + IFN-β</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon-β</intervention_name>
    <description>Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection</description>
    <arm_group_label>Teriflunomide 7 mg + IFN-β</arm_group_label>
    <arm_group_label>Teriflunomide 14 mg + IFN-β</arm_group_label>
    <arm_group_label>Placebo + IFN-β</arm_group_label>
    <other_name>Avonex®</other_name>
    <other_name>Rebif®</other_name>
    <other_name>Betaseron®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Definite MS diagnosis according to McDonald's criteria;

          -  Relapsing clinical course, with or without progression;

          -  Expanded Disability Status Scale [EDSS] less or equal to 5.5 (ambulatory);

          -  Stable dose of IFN-β for at least 26 weeks prior to the screening visit;

          -  No onset of MS relapse in the preceding 60 days prior to randomization;

          -  Clinically stable for 4 weeks prior to randomization.

        Exclusion Criteria:

          -  Other chronic disease of the immune system, liver function impairment or chronic
             pancreatic disease;

          -  Pregnant or nursing woman;

          -  Alcohol or drug abuse;

          -  Use of cladribine, mitoxantrone, or other immunosuppressant agents such as
             azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before
             enrollment;

          -  Human immunodeficiency virus [HIV] positive status;

          -  Any known condition or circumstance that would prevent in the investigator's opinion
             compliance or completion of the study.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Poland</country>
  </removed_countries>
  <results_reference>
    <citation>Freedman MS, Wolinsky JS, Wamil B, Confavreux C, Comi G, Kappos L, Olsson TP, Miller A, Benzerdjeb H, Li H, Simonson C, O'Connor PW; Teriflunomide Multiple Sclerosis Trial Group and the MRI Analysis Center. Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial. Neurology. 2012 Jun 5;78(23):1877-85. doi: 10.1212/WNL.0b013e318258f7d4. Epub 2012 May 23.</citation>
    <PMID>22622860</PMID>
  </results_reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2007</study_first_submitted>
  <study_first_submitted_qc>June 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2007</study_first_posted>
  <results_first_submitted>October 3, 2012</results_first_submitted>
  <results_first_submitted_qc>October 3, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 2, 2012</results_first_posted>
  <disposition_first_submitted>September 30, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>September 30, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 5, 2010</disposition_first_posted>
  <last_update_submitted>November 5, 2012</last_update_submitted>
  <last_update_submitted_qc>November 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MS</keyword>
  <keyword>interferon-beta</keyword>
  <keyword>adjunctive therapy</keyword>
  <keyword>relapses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment initiated in May 2007 was completed in August 2008. A total of 159 patients were screened at 29 sites in 5 countries.</recruitment_details>
      <pre_assignment_details>Randomization was stratified by country and dose level of interferon-β (high/low).
Assignment to groups was done centrally using an Interactive Voice Response System (IVRS] in a 1:1:1 ratio after confirmation of the selection criteria.
118 participants were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo + IFN-β</title>
          <description>Placebo (for teriflunomide) once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
        </group>
        <group group_id="P2">
          <title>Teriflunomide 7 mg + IFN-β</title>
          <description>Teriflunomide 7 mg once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
        </group>
        <group group_id="P3">
          <title>Teriflunomide 14 mg + IFN-β</title>
          <description>Teriflunomide 14 mg once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41">randomized</participants>
                <participants group_id="P2" count="37">randomized</participants>
                <participants group_id="P3" count="40">randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="39">One participant received teriflunomide 7 mg instead of teriflunomide 14 mg</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38">completed treatment period</participants>
                <participants group_id="P2" count="32">completed treatment period</participants>
                <participants group_id="P3" count="37">completed treatment period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not treated due to protocol violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant did not wish to continue</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than above</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo + IFN-β</title>
          <description>Placebo (for teriflunomide) once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
        </group>
        <group group_id="B2">
          <title>Teriflunomide 7 mg + IFN-β</title>
          <description>Teriflunomide 7 mg once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>Teriflunomide 14 mg + IFN-β</title>
          <description>Teriflunomide 14 mg once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="38"/>
            <count group_id="B4" value="116"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Baseline characteristics of the population included in the analyses: the 2 participants not treated were not included, and the participant who received teriflunomide 7 mg instead of teriflunomide 14 mg was included in the teriflunomide 7 mg group.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.2" spread="9.0"/>
                    <measurement group_id="B2" value="41.4" spread="6.8"/>
                    <measurement group_id="B3" value="39.6" spread="8.1"/>
                    <measurement group_id="B4" value="40.1" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Europe: Germany, Italy and Spain
North America: Canada and United States</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since first diagnosis of Multiple Sclerosis (MS)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.78" spread="5.62"/>
                    <measurement group_id="B2" value="8.35" spread="5.44"/>
                    <measurement group_id="B3" value="7.97" spread="6.59"/>
                    <measurement group_id="B4" value="8.38" spread="5.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of MS relapses</title>
          <units>MS relapses</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Within the past year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B2" value="0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="B3" value="1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="B4" value="1" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within the past 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="B2" value="1" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="B3" value="1" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B4" value="1" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since most recent MS relapse onset</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.68" spread="38.49"/>
                    <measurement group_id="B2" value="28.97" spread="34.06"/>
                    <measurement group_id="B3" value="24.71" spread="35.97"/>
                    <measurement group_id="B4" value="27.12" spread="36.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MS subtype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Relapsing Remitting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondary Progressive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Relapsing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Expanded Disability Status Scale (EDSS) score</title>
          <description>EDSS is an ordinal scale in half-point increments that qualifies disability in patients with MS. It consists of 8 ordinal rating scales assessing seven functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation.
EDSS total score ranges from 0 (normal neurological examination) to 10 (death due to MS).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.61" spread="1.26"/>
                    <measurement group_id="B2" value="2.41" spread="1.44"/>
                    <measurement group_id="B3" value="2.46" spread="1.57"/>
                    <measurement group_id="B4" value="2.50" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dose level of interferon-β</title>
          <description>'High dose': Rebif® 44 μg 3 times per week subcutaneously and, Betaseron® 0.25 mg every other day subcutaneously
'Low dose': Rebif® 22 μg 3 times per week subcutaneously and, Avonex® 30 μg once a week intramuscularly</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>High dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overview of Adverse Events [AE]</title>
        <description>AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.</description>
        <time_frame>from first study drug intake up to 112 days after last intake or up to the first intake in the extension study LTS6047, whichever occured first (40 weeks max)</time_frame>
        <population>All randomized and treated participants; Participants were included in the treatment group according to the drug actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + IFN-β</title>
            <description>Placebo (for teriflunomide) once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg + IFN-β</title>
            <description>Teriflunomide 7 mg once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg + IFN-β</title>
            <description>Teriflunomide 14 mg once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Overview of Adverse Events [AE]</title>
          <description>AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.</description>
          <population>All randomized and treated participants; Participants were included in the treatment group according to the drug actually received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- AE leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- AE leading to study drug discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overview of AE With Potential Risk of Occurrence</title>
        <description>AE with potential risk of occurrence were defined as follows:
Hepatic disorders;
Immune effects, mainly effects on bone marrow and infection;
Pancreatic disorders;
Malignancy;
Skin disorders, mainly Hair loss and Hair thinning;
Pulmonary disorders;
Hypertension;
Peripheral neuropathy;
Psychiatric disorders;
Hypersensitivity.</description>
        <time_frame>from first study drug intake up to 112 days after last intake or up to the first intake in the extension study LTS6047, whichever occured first (40 weeks max)</time_frame>
        <population>All randomized and treated participants; Participants were included in the treatment group according to the drug actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + IFN-β</title>
            <description>Placebo (for teriflunomide) once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg + IFN-β</title>
            <description>Teriflunomide 7 mg once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg + IFN-β</title>
            <description>Teriflunomide 14 mg once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Overview of AE With Potential Risk of Occurrence</title>
          <description>AE with potential risk of occurrence were defined as follows:
Hepatic disorders;
Immune effects, mainly effects on bone marrow and infection;
Pancreatic disorders;
Malignancy;
Skin disorders, mainly Hair loss and Hair thinning;
Pulmonary disorders;
Hypertension;
Peripheral neuropathy;
Psychiatric disorders;
Hypersensitivity.</description>
          <population>All randomized and treated participants; Participants were included in the treatment group according to the drug actually received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE with potential risk of occurence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Hepatic disorder AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Pancreatic disorder AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Pulmonary disorder AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Immune effects related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Hair loss / Hair thinning AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Hypertension-related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Peripheral neuropathy AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Hypersensitivity AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Malignancy AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Psychiatric disorder AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebral Magnetic Resonance Imaging [MRI] Assessment: Change From Baseline in Total Lesion Volume (Burden of Disease)</title>
        <description>Total lesion volume is the sum of the total volume of all T2-lesions and the total volume of all T1-hypointense post-gadolinium lesions measured through T2/proton density scan analysis and gadolinium-enhanced T1 scan analysis.
Least-square means were estimated using a Mixed-effect model with repeated measures [MMRM] on cubic root transformed volume data (treatment group, region of enrollment, IFN-β dose level, visit, treatment-by-visit interaction, baseline value (cubic root transformed), and baseline-by-visit interaction as factors).</description>
        <time_frame>baseline (before randomization) and 24 weeks</time_frame>
        <population>All randomized and treated participants; Participants were included in the treatment group according to the drug actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + IFN-β</title>
            <description>Placebo (for teriflunomide) once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg + IFN-β</title>
            <description>Teriflunomide 7 mg once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg + IFN-β</title>
            <description>Teriflunomide 14 mg once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebral Magnetic Resonance Imaging [MRI] Assessment: Change From Baseline in Total Lesion Volume (Burden of Disease)</title>
          <description>Total lesion volume is the sum of the total volume of all T2-lesions and the total volume of all T1-hypointense post-gadolinium lesions measured through T2/proton density scan analysis and gadolinium-enhanced T1 scan analysis.
Least-square means were estimated using a Mixed-effect model with repeated measures [MMRM] on cubic root transformed volume data (treatment group, region of enrollment, IFN-β dose level, visit, treatment-by-visit interaction, baseline value (cubic root transformed), and baseline-by-visit interaction as factors).</description>
          <population>All randomized and treated participants; Participants were included in the treatment group according to the drug actually received.</population>
          <units>mililiters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.001" spread="0.030"/>
                    <measurement group_id="O2" value="0.002" spread="0.032"/>
                    <measurement group_id="O3" value="-0.028" spread="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebral MRI Assessment: Number of Gd-enhancing T1-lesions Per Scan (Poisson Regression Estimates)</title>
        <description>Number of Gd-enhancing T1-lesions per scan is obtained from the total number of Gd-enhancing T1-lesions observed during the study divided by the total number of scans performed during the study.
To account for the different number of scans among participants, a Poisson regression model with robust error variance was used (total number of Gd-enhancing T1-lesions as response variable; log-transformed number of scans as &quot;offset&quot; variable; treatment group, region of enrollment, IFN-β dose level and baseline number of Gd-enhancing T1-lesions as covariates).</description>
        <time_frame>24 weeks</time_frame>
        <population>All randomized and treated participants; Participants were included in the treatment group according to the drug actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + IFN-β</title>
            <description>Placebo (for teriflunomide) once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg + IFN-β</title>
            <description>Teriflunomide 7 mg once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg + IFN-β</title>
            <description>Teriflunomide 14 mg once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebral MRI Assessment: Number of Gd-enhancing T1-lesions Per Scan (Poisson Regression Estimates)</title>
          <description>Number of Gd-enhancing T1-lesions per scan is obtained from the total number of Gd-enhancing T1-lesions observed during the study divided by the total number of scans performed during the study.
To account for the different number of scans among participants, a Poisson regression model with robust error variance was used (total number of Gd-enhancing T1-lesions as response variable; log-transformed number of scans as &quot;offset&quot; variable; treatment group, region of enrollment, IFN-β dose level and baseline number of Gd-enhancing T1-lesions as covariates).</description>
          <population>All randomized and treated participants; Participants were included in the treatment group according to the drug actually received.</population>
          <units>lesions per scan</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.570" lower_limit="0.350" upper_limit="0.929"/>
                    <measurement group_id="O2" value="0.099" lower_limit="0.041" upper_limit="0.241"/>
                    <measurement group_id="O3" value="0.089" lower_limit="0.050" upper_limit="0.159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebral MRI Assessment: Volume of Gd-enhancing T1-lesions Per Scan</title>
        <description>Total volume of Gd-enhancing T1-lesions per scan is obtained from the sum of the volumes of Gd-enhancing T1-lesions observed during the study divided by the total number of scans performed during the study.</description>
        <time_frame>24 weeks</time_frame>
        <population>All randomized and treated participants; Participants were included in the treatment group according to the drug actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + IFN-β</title>
            <description>Placebo (for teriflunomide) once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg + IFN-β</title>
            <description>Teriflunomide 7 mg once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg + IFN-β</title>
            <description>Teriflunomide 14 mg once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebral MRI Assessment: Volume of Gd-enhancing T1-lesions Per Scan</title>
          <description>Total volume of Gd-enhancing T1-lesions per scan is obtained from the sum of the volumes of Gd-enhancing T1-lesions observed during the study divided by the total number of scans performed during the study.</description>
          <population>All randomized and treated participants; Participants were included in the treatment group according to the drug actually received.</population>
          <units>mililiters per scan</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.068" spread="0.154"/>
                    <measurement group_id="O2" value="0.022" spread="0.149"/>
                    <measurement group_id="O3" value="0.024" spread="0.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Liver Function: Number of Participants With Potentially Clinically Significant Abnormalities (PCSA)</title>
        <description>PCSA values are abnormal values considered medically important by the Sponsor according to predefined criteria based on literature review.
Hepatic parameters thresholds were defined as follows:
Alanine Aminotransferase [ALT] &gt;3, 5, 10 or 20 Upper Normal Limit [ULN];
Aspartate aminotransferase [AST] &gt;3, 5, 10 or 20 ULN;
Alkaline Phosphatase &gt;1.5 ULN;
Total Bilirubin [TB] &gt;1.5 or 2 ULN;
ALT &gt;3 ULN and TB &gt;2 ULN;</description>
        <time_frame>from first study drug intake up to 112 days after last intake or up to the first intake in the extension study LTS6047, whichever occured first (40 weeks max)</time_frame>
        <population>All randomized and treated participants; Participants were included in the treatment group according to the drug actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + IFN-β</title>
            <description>Placebo (for teriflunomide) once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg + IFN-β</title>
            <description>Teriflunomide 7 mg once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg + IFN-β</title>
            <description>Teriflunomide 14 mg once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Function: Number of Participants With Potentially Clinically Significant Abnormalities (PCSA)</title>
          <description>PCSA values are abnormal values considered medically important by the Sponsor according to predefined criteria based on literature review.
Hepatic parameters thresholds were defined as follows:
Alanine Aminotransferase [ALT] &gt;3, 5, 10 or 20 Upper Normal Limit [ULN];
Aspartate aminotransferase [AST] &gt;3, 5, 10 or 20 ULN;
Alkaline Phosphatase &gt;1.5 ULN;
Total Bilirubin [TB] &gt;1.5 or 2 ULN;
ALT &gt;3 ULN and TB &gt;2 ULN;</description>
          <population>All randomized and treated participants; Participants were included in the treatment group according to the drug actually received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT &gt;3 ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- ALT &gt;5 ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST &gt;3 ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- AST &gt;5 ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase &gt;1.5 ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TB &gt;1.5 ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT &gt;3 ULN and TB &gt;2 ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Relapse Rate [ARR]: Poisson Regression Estimates</title>
        <description>ARR is obtained from the total number of confirmed relapses that occured during the treatment period divided by the sum of the treatment durations.
Each episode of relapse - appearance, or worsening of a clinical symptom that was stable for at least 30 days, that persisted for a minimum of 24 hours in the absence of fever - was to be confirmed by an increase in Expanded Disability Status Scale [EDSS] score or Functional System scores.
To account for the different treatment durations among participants, a Poisson regression model with robust error variance was used (total number of confirmed relapses as response variable; log-transformed treatment duration as &quot;offset&quot; variable; treatment group, region of enrollment and IFN-β dose level as covariates).</description>
        <time_frame>24 weeks</time_frame>
        <population>All randomized and treated participants; Participants were included in the treatment group according to the drug actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + IFN-β</title>
            <description>Placebo (for teriflunomide) once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg + IFN-β</title>
            <description>Teriflunomide 7 mg once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg + IFN-β</title>
            <description>Teriflunomide 14 mg once daily concomitantly with interferon-β (IFN-β) for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Relapse Rate [ARR]: Poisson Regression Estimates</title>
          <description>ARR is obtained from the total number of confirmed relapses that occured during the treatment period divided by the sum of the treatment durations.
Each episode of relapse - appearance, or worsening of a clinical symptom that was stable for at least 30 days, that persisted for a minimum of 24 hours in the absence of fever - was to be confirmed by an increase in Expanded Disability Status Scale [EDSS] score or Functional System scores.
To account for the different treatment durations among participants, a Poisson regression model with robust error variance was used (total number of confirmed relapses as response variable; log-transformed treatment duration as &quot;offset&quot; variable; treatment group, region of enrollment and IFN-β dose level as covariates).</description>
          <population>All randomized and treated participants; Participants were included in the treatment group according to the drug actually received.</population>
          <units>relapses per year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.260" lower_limit="0.108" upper_limit="0.625"/>
                    <measurement group_id="O2" value="0.280" lower_limit="0.101" upper_limit="0.774"/>
                    <measurement group_id="O3" value="0.109" lower_limit="0.031" upper_limit="0.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic [PK]: Teriflunomide Plasma Concentration</title>
        <description>Plasma concentrations of teriflunomide were measured using validated liquid chromatography-tandem mass spectrometry methods.</description>
        <time_frame>24 weeks</time_frame>
        <population>All randomized and treated participants who had at least one PK sample. Participants were included in the treatment group according to the drug actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriflunomide 7 mg + IFN-β</title>
            <description>Teriflunomide 7 mg once daily concomitantly with IFN-β for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 14 mg + IFN-β</title>
            <description>Teriflunomide 14 mg once daily concomitantly with IFN-β for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic [PK]: Teriflunomide Plasma Concentration</title>
          <description>Plasma concentrations of teriflunomide were measured using validated liquid chromatography-tandem mass spectrometry methods.</description>
          <population>All randomized and treated participants who had at least one PK sample. Participants were included in the treatment group according to the drug actually received.</population>
          <units>micrograms/mililiter (μg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.437" spread="16.034"/>
                    <measurement group_id="O2" value="47.761" spread="25.413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse Events (AE) were collected regardless of seriousness or relationship to the drug, spanning from signature of the Informed Consent Form up to the last visit.</time_frame>
      <desc>The analysis was performed on the exposed population and included all AE that developed or worsened from first study drug intake up to 112 days after last study drug intake or up to the first study drug intake in the extension study LTS6047, whichever occured first (40 weeks max)</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo + IFN-β</title>
          <description>Placebo (for teriflunomide) once daily concomitantly with IFN-β for 24 weeks</description>
        </group>
        <group group_id="E2">
          <title>Teriflunomide 7 mg + IFN-β</title>
          <description>Teriflunomide 7 mg once daily concomitantly with IFN-β for 24 weeks</description>
        </group>
        <group group_id="E3">
          <title>Teriflunomide 14 mg + + IFN-β</title>
          <description>Teriflunomide 14 mg once daily concomitantly with IFN-β for 24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator can publish only the results of the work performed pursuant to this protocol. Prior to publication, the investigator provides the sponsor with the manuscript for review and comment at least 45 days in advance of its submission for publication.
The sponsor can require the investigator to withhold publication an additional 90 days to allow for filing a patent application or taking such other measures as sponsor deems appropriate to establish and preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>sanofi-aventis</organization>
      <email>Contact_US@sanofi-aventis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

